We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CYAD market cap is 30.24M. The company's latest EPS is EUR -0.2039 and P/E is -3.58.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 6k | 5k | 0 | 0 | 102k |
| Operating Income | -28.88M | -16.99M | -26.39M | -40.86M | -9.54M |
| Net Income | -28.63M | -17.2M | -26.51M | -40.94M | -8.45M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 89.84M | 66.08M | 79.94M | 19.72M | 16.28M |
| Total Liabilities | 44.22M | 35.09M | 36.3M | 15.4M | 9.98M |
| Total Equity | 45.62M | 30.99M | 43.64M | 4.32M | 6.3M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -28.2M | -27.67M | -26.64M | -28.01M | -15.2M |
| Investing | 8.99M | 157k | -126k | 7.2M | 407k |
| Financing | 18.28M | 5.4M | 39.52M | 3.24M | 9.36M |
| Market Cap | 30.24M |
| Price to Earnings Ratio | -3.58 |
| Price to Sales Ratio | 292 |
| Price to Cash Ratio | 4.32 |
| Price to Book Ratio | 4.8 |
| Dividend Yield | - |
| Shares Outstanding | 41.43M |
| Average Volume (1 week) | 34.36k |
| Average Volume (1 Month) | 68.7k |
| 52 Week Change | 100.00% |
| 52 Week High | 1.22 |
| 52 Week Low | 0.212 |
| Spread (Intraday) | 0.03 (3.94%) |
| Company Name | Celyad Oncology SA |
| Address |
axis business park mont-saint-guibert, walloon brabant 1435 |
| Website | https://www.celyad.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
